PMCB (PharmaCyte Biotech) PS Ratio: (As of Jun. 30, 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.73
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, PharmaCyte Biotech's share price is $0.731. PharmaCyte Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2026 was $0.00. Hence, PharmaCyte Biotech's PS Ratio for today is .

The historical rank and industry rank for PharmaCyte Biotech's PS Ratio or its related term are showing as below:

PMCB's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.29
* Ranked among companies with meaningful PS Ratio only.

PharmaCyte Biotech's Revenue per Sharefor the three months ended in Jan. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2026 was $0.00.

During the past 13 years, PharmaCyte Biotech's highest 3-Year average Revenue per Share Growth Rate was 596.90% per year. The lowest was -68.50% per year. And the median was -50.60% per year.

Back to Basics: PS Ratio


PharmaCyte Biotech  (NAS:PMCB) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


PharmaCyte Biotech PS Ratio Related Terms


PharmaCyte Biotech PS Ratio Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech PS Ratio Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PMCB vs ERNA, SYBX, ASBP: PS Ratio Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's PS Ratio distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's PS Ratio falls into.


PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

PharmaCyte Biotech's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.731/0
=

PharmaCyte Biotech's Share Price of today is $0.731.
PharmaCyte Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price